Cosmos Health Inc (COSM)

$0.21 +0.00 (0.78%)
Market Cap 12.31M
Revenue (ttm) 65.27M
Net Income (ttm) -19.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 21.79
Profit Margin -29.34%
Debt to Equity Ratio 0.46
Volume 2,709,400
Avg Vol 11,791,452
Day's Range N/A - N/A
Shares Out 60.04M
Stochastic %K 12%
Beta 4.80
Analysts Strong Buy
Price Target $4.50

Company Profile

Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogre...

Industry: Medical Distribution
Sector: Healthcare
Phone: 312 536 3102
Address:
5 Agiou Georgiou Str, Pilea, Thessaloniki, Greece
SHEEPWOLF
SHEEPWOLF Aug. 19 at 11:46 AM
$COSM Focusing on Core Operations vs. Accounting Noise •buying opp, just off 52 week lows Don't let the headline net loss fool you on $COSM . Look under the hood: Q2 revenue surged 29% YoY to $18.99M. The wider net loss was heavily skewed by non-cash charges on digital assets/notes and a one-time $0.8M revenue reversal. Actual operating losses narrowed to $2.9M. 📈🔍
0 · Reply
kalbany
kalbany Aug. 19 at 11:45 AM
$COSM ready for the climb back up. Hope you bought the dip
0 · Reply
Stopcryin
Stopcryin Aug. 19 at 11:24 AM
$COSM Snorting, injecting or swallowing?
0 · Reply
El_Stocks
El_Stocks Aug. 19 at 9:39 AM
$COSM read between the lines. a smart analyst would look beyond the share count / losses and look at the trend and overall structure. 1) 2025 August notes have been repaid via conversions. This is big news meaning no more overhang from this challenging financial instrument. Yes the share count went up but also debt went down a lot, and no more hefty interest payments. In other words the balance sheet is in better shape and no more selling pressure. 2) revenue growth is booming! This is happening across all divisions. And this seems to be carrying into Q3. 3) there is built in M&A growth in the pipeline, in addition to strong organic performance 4) liquid assets from the balance sheet exceed $5 million , if not more. Besides cash, we also have the crypto portfolio which can be sold at any moment 5) there are $20 million in non-core assets that can be monetized 6) active buyback program in place likely paused due to quiet period
0 · Reply
Skoufa
Skoufa Aug. 19 at 8:47 AM
$COSM its simple. Too much fixation on the shares while missing the bigger picture. There is no more selling pressure from the August 2025 notes. This largely explains the shares , but on the flip side debt is down substantially , and interest payments will go down. They are buying back their shares which means the share count can go down by a lot at current levels . Revenue is rising by 30%. They have over $4 million in liquid assets, mostly cash and cryptos $ETH.X and $BTC.X.
0 · Reply
Skoufa
Skoufa Aug. 19 at 8:44 AM
$COSM what are you celebrating exactly? They have the assets to buy back the company and take it private. There is no more selling pressure from the August 2025 notes. Debt is down, interest payments will go down. They are buying back shares. Revenue is rising by 30%. And the list goes on!
0 · Reply
Stopcryin
Stopcryin Aug. 19 at 8:39 AM
$COSM To the many thousands here letsgetpaid, gio, P131, Tommy, just to name a few, who thought they would be the first to burn me ... don't do it, your family hopefully still loves you and plus, your money went to a great cause ... people like me 😊
0 · Reply
Skoufa
Skoufa Aug. 19 at 8:35 AM
$COSM huge news on pg 49 of the 10Q. It clearly explains that the August 2025 has been essentially fully addressed!! In other words, no more overhang and selling pressure on the share price due to convertibles! And the company is buying back shares now, while debt has fallenc and of course interest payments have fallen as a result! The August note is no longer there to cause selling pressure!!
0 · Reply
Stopcryin
Stopcryin Aug. 19 at 8:32 AM
$COSM You sure did !! 🤣😂🤣
0 · Reply
Skoufa
Skoufa Aug. 19 at 8:31 AM
$COSM too much panic for the share count change. Page 49 of the 10Q sets the story straight. The August 2025 has been addressed pretty much in full (only $82,500 remaining). As a result, the share count increased BUT debt also fell substantially. AND the company is not buying back shares, and they have over than $4 million in liquid assets, and they can sell their $ETC.X and $BTC.X to raise cash, and they also have over $15 million in real estate that can be monetised if need be. Importantly, the is no more convertible debt pressure on the share price!!
0 · Reply
Latest News on COSM
Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels

Jul 27, 2026, 1:05 PM EDT - 22 days ago

Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels

Cosmos Health expands Sky Premium Life distribution pact with Pharma Cell

2026-07-20T19:50:15.000Z - 4 weeks ago

Cosmos Health expands Sky Premium Life distribution pact with Pharma Cell

Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units

Jul 20, 2026, 3:46 PM EDT - 4 weeks ago

Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units

Cosmos Health Share Buyback Expands to 5.11 Million Shares; Continues Open Market Repurchases

Jul 17, 2026, 2:55 PM EDT - 4 weeks ago

Cosmos Health Share Buyback Expands to 5.11 Million Shares; Continues Open Market Repurchases

Cosmos Health announces repurchase of additional 250,000 shares

2026-07-16T17:20:22.000Z - 4 weeks ago

Cosmos Health announces repurchase of additional 250,000 shares

Cosmos Health Share Buyback Surpasses $1 Million, Reaching 4.84 Million Shares; Continues Open Market Repurchases

Jul 16, 2026, 1:15 PM EDT - 4 weeks ago

Cosmos Health Share Buyback Surpasses $1 Million, Reaching 4.84 Million Shares; Continues Open Market Repurchases

Cosmos Health announces repurchase of additional 100,000 shares

2026-07-15T18:20:12.000Z - 4 weeks ago

Cosmos Health announces repurchase of additional 100,000 shares

Cosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases

Jul 15, 2026, 2:15 PM EDT - 4 weeks ago

Cosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases

Cosmos Health stock buyback expands to 4.49M shares

2026-07-14T18:45:10.000Z - 5 weeks ago

Cosmos Health stock buyback expands to 4.49M shares

Cosmos Health Share Buyback Expands to 4.49 Million Shares; Continues Open Market Repurchases

Jul 14, 2026, 2:40 PM EDT - 5 weeks ago

Cosmos Health Share Buyback Expands to 4.49 Million Shares; Continues Open Market Repurchases

Cosmos Health repurchases additional 215,000 common shares in open market

2026-07-13T19:05:14.000Z - 5 weeks ago

Cosmos Health repurchases additional 215,000 common shares in open market

Cosmos Health Share Buyback Reaches 4.36 Million Shares; Continues Open Market Repurchases

Jul 13, 2026, 3:00 PM EDT - 5 weeks ago

Cosmos Health Share Buyback Reaches 4.36 Million Shares; Continues Open Market Repurchases

Cosmos Health reports Libytec partnership to commercialize Diabit-IS X in Greece

2026-07-13T17:05:17.000Z - 5 weeks ago

Cosmos Health reports Libytec partnership to commercialize Diabit-IS X in Greece

Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece

Jul 13, 2026, 1:00 PM EDT - 5 weeks ago

Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece

Cosmos Health launches subscription model

2026-07-10T15:00:12.000Z - 5 weeks ago

Cosmos Health launches subscription model

Cosmos Health Launches Subscription Model

Jul 10, 2026, 10:55 AM EDT - 5 weeks ago

Cosmos Health Launches Subscription Model

Cosmos Health announces repurchase of additional 80,000 shares

2026-07-09T19:50:56.000Z - 5 weeks ago

Cosmos Health announces repurchase of additional 80,000 shares

Cosmos Health Expands Share Buyback to 4.14 Million Shares; Continues Open Market Repurchases

Jul 9, 2026, 3:45 PM EDT - 5 weeks ago

Cosmos Health Expands Share Buyback to 4.14 Million Shares; Continues Open Market Repurchases

Cosmos Health announces repurchase of additional 190,000 shares

2026-07-08T19:55:19.000Z - 5 weeks ago

Cosmos Health announces repurchase of additional 190,000 shares

Cosmos Health Share Buyback Surpasses 4 Million Shares; Continues Open Market Repurchases

Jul 8, 2026, 3:40 PM EDT - 5 weeks ago

Cosmos Health Share Buyback Surpasses 4 Million Shares; Continues Open Market Repurchases

Cosmos Health announces repurchase of additional 230,000 shares

2026-07-07T18:30:11.000Z - 6 weeks ago

Cosmos Health announces repurchase of additional 230,000 shares

Cosmos Health Share Buyback Expands to 3.87 Million Shares; Continues Open Market Repurchases

Jul 7, 2026, 2:27 PM EDT - 6 weeks ago

Cosmos Health Share Buyback Expands to 3.87 Million Shares; Continues Open Market Repurchases

Cosmos Health reports preliminary Q2 revenue $19.4M

2026-07-07T13:35:24.000Z - 6 weeks ago

Cosmos Health reports preliminary Q2 revenue $19.4M

Cosmos Health Reports Preliminary Record Q2 and H1 2026 Revenue, Up Over 30% Year-Over-Year; Continues Open Market Share Repurchases

Jul 7, 2026, 9:29 AM EDT - 6 weeks ago

Cosmos Health Reports Preliminary Record Q2 and H1 2026 Revenue, Up Over 30% Year-Over-Year; Continues Open Market Share Repurchases

Cosmos Health announces repurchase of additional 220,000 shares

2026-07-06T18:40:08.000Z - 6 weeks ago

Cosmos Health announces repurchase of additional 220,000 shares

Cosmos Health Share Buyback Increases to 3.64 Million Shares; Continues Open Market Purchases

Jul 6, 2026, 2:30 PM EDT - 6 weeks ago

Cosmos Health Share Buyback Increases to 3.64 Million Shares; Continues Open Market Purchases

Cosmos Health expands buyback with additional 770,000 share repurchase

2026-07-02T18:15:08.000Z - 6 weeks ago

Cosmos Health expands buyback with additional 770,000 share repurchase

Cosmos Health Expands Buyback to 3.42 Million Shares With Additional 770,000-Share Repurchase; Continues Open Market Purchases

Jul 2, 2026, 2:10 PM EDT - 6 weeks ago

Cosmos Health Expands Buyback to 3.42 Million Shares With Additional 770,000-Share Repurchase; Continues Open Market Purchases

Cosmos Health Completes Initial Repurchase of 2.65 Million Shares for $500,000; Continues Open Market Buybacks at Current Pace

Jul 1, 2026, 11:05 AM EDT - 6 weeks ago

Cosmos Health Completes Initial Repurchase of 2.65 Million Shares for $500,000; Continues Open Market Buybacks at Current Pace

Cosmos Health authorizes up to $5M share repurchase program

2026-06-30T16:00:32.000Z - 7 weeks ago

Cosmos Health authorizes up to $5M share repurchase program

Cosmos Health Authorizes Up to $5 Million Share Repurchase Program

Jun 30, 2026, 11:55 AM EDT - 7 weeks ago

Cosmos Health Authorizes Up to $5 Million Share Repurchase Program

Cosmos Health signs distribution agreement with IMC

2026-06-26T16:35:09.000Z - 7 weeks ago

Cosmos Health signs distribution agreement with IMC

Cosmos Health Signs Distribution Agreement With IMC, Owner of Qatar's Largest Pharmacy Chain; Secures Initial Purchase Order of 31,000 Sky Premium Life Units

Jun 26, 2026, 12:30 PM EDT - 7 weeks ago

Cosmos Health Signs Distribution Agreement With IMC, Owner of Qatar's Largest Pharmacy Chain; Secures Initial Purchase Order of 31,000 Sky Premium Life Units

Cosmos Health’s Cana advances international patent application

2026-06-25T19:40:17.000Z - 7 weeks ago

Cosmos Health’s Cana advances international patent application

Cosmos Health Advances International Patent Application for Its Proprietary Hydrogel Weight Management Platform Across the U.S., Europe, Australia, and Canada

Jun 25, 2026, 3:31 PM EDT - 7 weeks ago

Cosmos Health Advances International Patent Application for Its Proprietary Hydrogel Weight Management Platform Across the U.S., Europe, Australia, and Canada

Cosmos Health's C-Sept PRO Gains Strong Traction Across Leading Greek Public and Private Hospital Groups, With Annualized Sales Poised to Exceed $1.3 Million at Approximately 72% Gross Margin

Jun 24, 2026, 3:37 PM EDT - 7 weeks ago

Cosmos Health's C-Sept PRO Gains Strong Traction Across Leading Greek Public and Private Hospital Groups, With Annualized Sales Poised to Exceed $1.3 Million at Approximately 72% Gross Margin

Cosmos Health to deploy AI-powered call center

2026-06-23T19:40:11.000Z - 2 months ago

Cosmos Health to deploy AI-powered call center

Cosmos Health Signs Agreement to Deploy Artificial Intelligence (AI)-Powered Call Center to Optimize Order Intake, Customer Communications, and Operating Efficiency

Jun 23, 2026, 3:35 PM EDT - 2 months ago

Cosmos Health Signs Agreement to Deploy Artificial Intelligence (AI)-Powered Call Center to Optimize Order Intake, Customer Communications, and Operating Efficiency

Cosmos Health builds contract manufacturing orderbook to over 25M units

2026-06-22T14:40:08.000Z - 2 months ago

Cosmos Health builds contract manufacturing orderbook to over 25M units

Cosmos Health Builds Contract Manufacturing Orderbook to Over 25 Million Units; Division Positioned to Generate Over $10 Million in Recurring Annual Profit

Jun 22, 2026, 10:30 AM EDT - 2 months ago

Cosmos Health Builds Contract Manufacturing Orderbook to Over 25 Million Units; Division Positioned to Generate Over $10 Million in Recurring Annual Profit

CosmoFarm Delivers Record Q2 2026 Revenue of Over $15M, Representing $60+ Million Annualized Run-Rate; Adds Over 80 Pharmacies and Expands AI Automation and Facility Capacity

Jun 18, 2026, 3:34 PM EDT - 2 months ago

CosmoFarm Delivers Record Q2 2026 Revenue of Over $15M, Representing $60+ Million Annualized Run-Rate; Adds Over 80 Pharmacies and Expands AI Automation and Facility Capacity

Cosmos Health Enters the $163 Billion Global Skincare Market; Sales Already Underway in the United States

Jun 17, 2026, 3:35 PM EDT - 2 months ago

Cosmos Health Enters the $163 Billion Global Skincare Market; Sales Already Underway in the United States

Cosmos Health Signs 2.86 Million-Unit Contract Manufacturing Agreement With Pharmex S.A. Across Three Dermatological Products

Jun 17, 2026, 9:27 AM EDT - 2 months ago

Cosmos Health Signs 2.86 Million-Unit Contract Manufacturing Agreement With Pharmex S.A. Across Three Dermatological Products

Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit

Jun 15, 2026, 9:00 AM EDT - 2 months ago

Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit

Cosmos Health’s Cana wins contract manufacturing orders totaling 253,657 units

2026-06-12T19:40:29.000Z - 2 months ago

Cosmos Health’s Cana wins contract manufacturing orders totaling 253,657 units

Cosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines

Jun 12, 2026, 3:33 PM EDT - 2 months ago

Cosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines

Cosmos Health Reports Annualized Sales Exceeding $1.5M for Its C-Scrub and C-Sept Antiseptic Brands in the UK and Greece; Plans EU Expansion Targeting $7.4M in Revenue and $5.3M in Gross Profit

Jun 12, 2026, 9:29 AM EDT - 2 months ago

Cosmos Health Reports Annualized Sales Exceeding $1.5M for Its C-Scrub and C-Sept Antiseptic Brands in the UK and Greece; Plans EU Expansion Targeting $7.4M in Revenue and $5.3M in Gross Profit

Cosmos Health to acquire Doc Pharma, terms undisclosed

2026-06-11T19:35:09.000Z - 2 months ago

Cosmos Health to acquire Doc Pharma, terms undisclosed

Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio

Jun 11, 2026, 3:31 PM EDT - 2 months ago

Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio

Cosmos Health Signs 3-Year Contract Manufacturing Agreement with Verisfield for 3.9 Million Units of VASCLOR GEST Progesterone Pessaries

Jun 10, 2026, 3:32 PM EDT - 2 months ago

Cosmos Health Signs 3-Year Contract Manufacturing Agreement with Verisfield for 3.9 Million Units of VASCLOR GEST Progesterone Pessaries

Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway

Jun 10, 2026, 9:00 AM EDT - 2 months ago

Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway

Cosmos Health Inaugurates State-of-the-Art Capsule Production Line with New 5-Year Contract Manufacturing Agreement with Provident Pharmaceuticals for 385,000 Units of CERTORUN

Jun 9, 2026, 3:30 PM EDT - 2 months ago

Cosmos Health Inaugurates State-of-the-Art Capsule Production Line with New 5-Year Contract Manufacturing Agreement with Provident Pharmaceuticals for 385,000 Units of CERTORUN

Cosmos Health Completes Acquisition of Strategic Intellectual Property and Expands Nanotechnology Investment Initiatives

Jun 8, 2026, 10:00 AM EDT - 2 months ago

Cosmos Health Completes Acquisition of Strategic Intellectual Property and Expands Nanotechnology Investment Initiatives

Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories

Jun 5, 2026, 9:25 AM EDT - 2 months ago

Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories

Cosmos Health Achieves Pan-European Distribution for Sky Premium Life Across All 27 EU Member States Through Leading E-Commerce Platform Skroutz

Jun 4, 2026, 3:57 PM EDT - 2 months ago

Cosmos Health Achieves Pan-European Distribution for Sky Premium Life Across All 27 EU Member States Through Leading E-Commerce Platform Skroutz

Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value

Jun 4, 2026, 9:25 AM EDT - 2 months ago

Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value

Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657

Jun 1, 2026, 8:25 AM EDT - 2 months ago

Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657

Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation

May 26, 2026, 9:34 AM EDT - 3 months ago

Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation

Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants

May 21, 2026, 2:20 PM EDT - 3 months ago

Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants

Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway

May 21, 2026, 9:15 AM EDT - 3 months ago

Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway

Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt Program

May 14, 2026, 9:00 AM EDT - 3 months ago

Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt Program

Cosmos Health Announces Withdrawal of Registration Statement on Form S-1

May 12, 2026, 10:15 AM EDT - 3 months ago

Cosmos Health Announces Withdrawal of Registration Statement on Form S-1

Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months

May 11, 2026, 2:25 PM EDT - 3 months ago

Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months

Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed

May 8, 2026, 11:25 AM EDT - 3 months ago

Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed

Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months

Apr 30, 2026, 12:50 PM EDT - 3 months ago

Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months

Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products

Apr 21, 2026, 12:50 PM EDT - 4 months ago

Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products

Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio

Apr 20, 2026, 10:55 AM EDT - 4 months ago

Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio

Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health

Apr 17, 2026, 2:00 PM EDT - 4 months ago

Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health

Cosmos Health Advances AI Investments to Enhance Efficiency, Reduce Costs, Improve Customer Experience and Drive Sales Growth; Certain Operating Expenses May Decrease by Up to 30%

Apr 16, 2026, 3:15 PM EDT - 4 months ago

Cosmos Health Advances AI Investments to Enhance Efficiency, Reduce Costs, Improve Customer Experience and Drive Sales Growth; Certain Operating Expenses May Decrease by Up to 30%

Cosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash Position Up 10x to $3.5M; Record Growth Continues Into 2026 Across All Core Segments

Apr 15, 2026, 9:25 AM EDT - 4 months ago

Cosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash Position Up 10x to $3.5M; Record Growth Continues Into 2026 Across All Core Segments

SHEEPWOLF
SHEEPWOLF Aug. 19 at 11:46 AM
$COSM Focusing on Core Operations vs. Accounting Noise •buying opp, just off 52 week lows Don't let the headline net loss fool you on $COSM . Look under the hood: Q2 revenue surged 29% YoY to $18.99M. The wider net loss was heavily skewed by non-cash charges on digital assets/notes and a one-time $0.8M revenue reversal. Actual operating losses narrowed to $2.9M. 📈🔍
0 · Reply
kalbany
kalbany Aug. 19 at 11:45 AM
$COSM ready for the climb back up. Hope you bought the dip
0 · Reply
Stopcryin
Stopcryin Aug. 19 at 11:24 AM
$COSM Snorting, injecting or swallowing?
0 · Reply
El_Stocks
El_Stocks Aug. 19 at 9:39 AM
$COSM read between the lines. a smart analyst would look beyond the share count / losses and look at the trend and overall structure. 1) 2025 August notes have been repaid via conversions. This is big news meaning no more overhang from this challenging financial instrument. Yes the share count went up but also debt went down a lot, and no more hefty interest payments. In other words the balance sheet is in better shape and no more selling pressure. 2) revenue growth is booming! This is happening across all divisions. And this seems to be carrying into Q3. 3) there is built in M&A growth in the pipeline, in addition to strong organic performance 4) liquid assets from the balance sheet exceed $5 million , if not more. Besides cash, we also have the crypto portfolio which can be sold at any moment 5) there are $20 million in non-core assets that can be monetized 6) active buyback program in place likely paused due to quiet period
0 · Reply
Skoufa
Skoufa Aug. 19 at 8:47 AM
$COSM its simple. Too much fixation on the shares while missing the bigger picture. There is no more selling pressure from the August 2025 notes. This largely explains the shares , but on the flip side debt is down substantially , and interest payments will go down. They are buying back their shares which means the share count can go down by a lot at current levels . Revenue is rising by 30%. They have over $4 million in liquid assets, mostly cash and cryptos $ETH.X and $BTC.X.
0 · Reply
Skoufa
Skoufa Aug. 19 at 8:44 AM
$COSM what are you celebrating exactly? They have the assets to buy back the company and take it private. There is no more selling pressure from the August 2025 notes. Debt is down, interest payments will go down. They are buying back shares. Revenue is rising by 30%. And the list goes on!
0 · Reply
Stopcryin
Stopcryin Aug. 19 at 8:39 AM
$COSM To the many thousands here letsgetpaid, gio, P131, Tommy, just to name a few, who thought they would be the first to burn me ... don't do it, your family hopefully still loves you and plus, your money went to a great cause ... people like me 😊
0 · Reply
Skoufa
Skoufa Aug. 19 at 8:35 AM
$COSM huge news on pg 49 of the 10Q. It clearly explains that the August 2025 has been essentially fully addressed!! In other words, no more overhang and selling pressure on the share price due to convertibles! And the company is buying back shares now, while debt has fallenc and of course interest payments have fallen as a result! The August note is no longer there to cause selling pressure!!
0 · Reply
Stopcryin
Stopcryin Aug. 19 at 8:32 AM
$COSM You sure did !! 🤣😂🤣
0 · Reply
Skoufa
Skoufa Aug. 19 at 8:31 AM
$COSM too much panic for the share count change. Page 49 of the 10Q sets the story straight. The August 2025 has been addressed pretty much in full (only $82,500 remaining). As a result, the share count increased BUT debt also fell substantially. AND the company is not buying back shares, and they have over than $4 million in liquid assets, and they can sell their $ETC.X and $BTC.X to raise cash, and they also have over $15 million in real estate that can be monetised if need be. Importantly, the is no more convertible debt pressure on the share price!!
0 · Reply
Skoufa
Skoufa Aug. 19 at 8:20 AM
$COSM the company is growing and paying down debt. Perhaps they will accelerate buybacks now.
0 · Reply
Skoufa
Skoufa Aug. 19 at 8:19 AM
$COSM staying the course , cause there is a great anchor business Cosmofarm providing stable and increasing cashflows, providing the ability to fund higher margin projects like Contract Manufacturing, Proprietary Brands, US Expansion, R&D, and more like entry into animal healthcare.
0 · Reply
Stopcryin
Stopcryin Aug. 19 at 8:14 AM
$COSM Here's to CEO Siokas @Akis1965 WE DID IT !! 🤣🤑🤑🤑🤣
0 · Reply
Mmmm_
Mmmm_ Aug. 19 at 6:44 AM
$COSM There is a possibility that the newly issued shares did not necessarily come directly from the company. What I find suspicious is this: The company announced that it intended to recover the $1 level, yet somehow, within just a month and a half, the number of outstanding shares increased by approximately 20 million shares. That is a massive increase in such a short period of time, and I find the timing extremely suspicious. On top of that, during the same period, the company suddenly released a preliminary revenue announcement. But after seeing today’s actual earnings results, the company reported significant losses and the overall results were very disappointing. Could all of this really be a coincidence? The increase in shares also seems to be too large to be explained by the remaining potential shares alone. If these additional shares did not come from the company’s ATM program, then what exactly were these shares? I am genuinely curious about that myself.
0 · Reply
Mmmm_
Mmmm_ Aug. 19 at 6:28 AM
$COSM PAGE 3 At this point, it appears increasingly likely that the company is preparing for a reverse stock split. The concern is that the company could continue issuing shares and generating proceeds until the stock price falls further, and then conduct a reverse split to reduce the number of shares outstanding. The latest filing has revealed just how dramatically the share count has increased. From approximately 30–36 million shares last year, to more than 80 million by June 30, and now 100,633,773 shares as of August 18. There may still be tens of millions of additional shares available through ATM financing, convertible securities, and warrants. If management truly intended to restore the stock price to $1, why would it issue such a massive amount of stock at these prices? The dilution speaks for itself. Shareholders deserve clear answers about how many more shares can still be issued and what management’s real intentions are.
0 · Reply
Mmmm_
Mmmm_ Aug. 19 at 6:23 AM
$COSM PAGE 2 The company previously talked about its intention to recover the $1 level and gave shareholders hope that the stock price would recover. But while management was talking about getting the stock back to $1, it was simultaneously issuing and selling a massive number of new shares behind the scenes. The latest filing has now revealed just how significant this share issuance was. That is what is most disturbing to shareholders. If management genuinely intended to increase the stock price, why would it issue and sell tens of millions of shares at these extremely low prices? The latest filing appears to have exposed what was happening behind the scenes: while shareholders were being told to expect a recovery toward $1, the company was substantially increasing the share count and selling new shares into the market. This creates enormous dilution for existing shareholders and raises serious questions about management’s intentions.
0 · Reply
Mmmm_
Mmmm_ Aug. 19 at 6:22 AM
$COSM PAGE 1 Shareholders Have Been Completely Misled. I am a foreign investor, and because I do not speak English, I carefully translated and read through the company’s filings in full. According to the latest filing, outstanding shares as of August 18 were 100,633,773 shares. At the end of last year, there were only around 30–36 million shares. That means the share count has nearly tripled. What does that mean for shareholders? It means the value represented by each existing share has been heavily diluted compared with last year. On June 30, there were approximately 80 million shares outstanding. In just over one month, another 20 million shares were added. And this may not be the end. There are still ATM shares and other potentially dilutive securities that could add tens of millions of additional shares.
0 · Reply
PutridCoast
PutridCoast Aug. 19 at 5:44 AM
$COSM welp.. :p now we wait to see how many shares there are
0 · Reply
Mmmm_
Mmmm_ Aug. 19 at 4:04 AM
$COSM It’s still quite shocking. The company had previously released preliminary revenue figures, which made it seem as though the earnings were going to be strong. Generally, when a company announces preliminary revenue ahead of its full earnings report, the market tends to take that as a positive sign that the overall results are likely to be good. But when the actual earnings were finally released, it was shocking to see that the company’s losses had more than doubled compared with last year. For shareholders who had been waiting for about two months, I think the sense of disappointment—and even betrayal by the company—is going to be pretty strong. That’s why we’re seeing so much disappointment-driven selling today.
0 · Reply
Stopcryin
Stopcryin Aug. 19 at 3:53 AM
$COSM You people are in bad denial ... get help! You got played by this crooked CEO and lost bigly! Tomorrow when this hits a new 52Wk low (and it will easily) you still will be trying to bury your head in the sand and defend him. If I knew net profits were going to be a disaster, don't you think this CEO did too ... all while misleading you dummies into thinking this quarter was going to be great. face it ... he got you all again, but this time there's no coming back! Only question left is bankruptcy or OTC? Oh and I guess you can call this a "last resort" for that RS? LMAO!
0 · Reply
BearTrapperA57
BearTrapperA57 Aug. 19 at 3:30 AM
$COSM If anything he pumps this post reverse split low float, despite the bashers any stock can run against fundamentals
0 · Reply
Mmmm_
Mmmm_ Aug. 19 at 3:09 AM
$COSM We need to be realistic and make a rational judgment right now. Normally, you can praise a company when its stock price keeps rising and its performance is proving itself. But in this case, the company’s losses are increasing, there are significant concerns about potential shareholder dilution, and the stock price keeps hitting new lows. On top of that, the company even faces the risk of being delisted. Of course, if some huge catalyst were to emerge—such as the company signing a massive revenue-generating contract with a major corporation, securing a government contract, or a major player like Intel or Elon Musk buying a stake in the company—or if the company were up for sale and news broke that a major corporation was acquiring it, then sure, the stock could potentially go up 100x. If there were a company like that, I’d be the first to buy its stock.
1 · Reply